Drug intelligence / Profile preview

anti-PD-L1-800

Development stage
Preclinical
Lead developer
Massachusetts Eye and Ear
Modality
Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

anti-PD-L1-800 is a fluorescently labeled monoclonal antibody probe designed for the noninvasive detection and quantification of Programmed Death-Ligand 1 (PD-L1) expression. It consists of an anti-PD-L1 antibody conjugated to the near-infrared (NIR) fluorophore IRDye 800CW. The agent is utilized in fluorescence lifetime (FLT) tomography to distinguish between bound and unbound probes, allowing for spatially resolved mapping of PD-L1 in deep-seated tumors, such as liver cancer. This diagnostic tool aims to improve the assessment of PD-L1 heterogeneity and guide immunotherapy selection by providing a more accurate, in vivo alternative to traditional ex vivo immunohistochemistry.

Other names
anti-PD-L1 antibody conjugated to IRDye 800CWanti-PD-L-1 antibody conjugated to IRDye 800CWanti-PD-L 1 antibody conjugated to IRDye 800CWanti-PD-L1-IRDye 800CWanti-PD-L-1-IRDye 800CWanti-PD-L 1-IRDye 800CW
02

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on anti-PD-L1-800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-PD-L1-800.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call